PSAT1 and cholangiocarcinoma: In cholangiocarcinoma, the combination of BET degradation and mTOR inhibition synergistically reduces acetylation of PSAT1-H3K27, inducing PSAT1 downregulation and subsequent SGOC pathway dysfunction [113].